alexa Mining the Breast Cancer Proteome for Predictors of Drug Sensitivity

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Mining the Breast Cancer Proteome for Predictors of Drug Sensitivity

The U.S. Food and Drug Administration has approved roughly two dozen drugs for breast cancer treatment, but only a few predictivebiomarkers are currently available to guide their use. For example, levels of the estrogen or progesterone receptor have been found to predict sensitivity to compounds that interfere with estrogen receptor signaling, and, the over-expression of human epidermal growth factor receptor 2 (HER2) predicts sensitivity to pertuzumab, trastuzumab and lapatinib. Additional biomarkers would be of significant value for determining the sensitivity of tumors to drugs already approved for clinical use in breast cancer, as well as for new drug development [1,2].

Citation: Timpe LC, Li D, Yen TY, Wong J, Yen R, et al. (2015) Mining the Breast Cancer Proteome for Predictors of Drug Sensitivity. J Proteomics Bioinform 8:204-211

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger